No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients

Mediators Inflamm. 2004 Dec;13(5-6):377-80. doi: 10.1080/09629350400014131.

Abstract

Background: Ozone as a strong oxidant may induce an inflammatory response.

Aim: The hypothesis was verified as to whether ozonated autohemotherapy using an ozone dose in therapeutic range changes the plasma concentration of C-reactive protein and interleukin-6, markers of inflammation.

Methods: In a controlled, single-blind, cross-over study, 12 chronically hemodialyzed patients with peripheral arterial disease were exposed to nine sessions of autohemotherapy with blood exposure to oxygen as a control followed by nine sessions of ozonated autohemotherapy with an ozone concentration of 50 microg/ml.

Results: There was no statistical difference between C-reactive protein levels at baseline (1.53 +/- 1.01 mg/l), after nine sessions of control autohemotherapy (1.48 +/- 0.96 mg/l), and after nine sessions of ozonated autohemotherapy (1.55 +/- 0.84 mg/l). There was also no statistical difference between the interleukin-6 serum concentration at baseline (438 +/- 118 pg/ml), after nine sessions of control autohemotherapy (444 +/- 120 pg/ml), and after nine sessions of ozonated autohemotherapy (466 +/- 152 pg/ml).

Conclusion: The results of this study suggest that ozonated autohemotherapy using an ozone concentration of 50 microg/ml does not induce an inflammatory response.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • C-Reactive Protein / metabolism
  • Cross-Over Studies
  • Humans
  • Inflammation Mediators / metabolism*
  • Interleukin-6 / blood
  • Ozone / adverse effects
  • Ozone / therapeutic use*
  • Peripheral Vascular Diseases / blood
  • Peripheral Vascular Diseases / drug therapy
  • Renal Dialysis*
  • Safety
  • Single-Blind Method

Substances

  • Inflammation Mediators
  • Interleukin-6
  • Ozone
  • C-Reactive Protein